Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Single and Multiple Escalating Doses of ODM-108: A Single Centre Study in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 07 Jul 2017
At a glance
- Drugs ODM 108 (Primary) ; Midazolam
- Indications Neuropathic pain
- Focus Adverse reactions
- Acronyms FIMTRIP
- Sponsors Orion
- 16 Aug 2016 Planned End Date changed from 1 Nov 2016 to 1 Sep 2016.
- 16 Aug 2016 Status changed from recruiting to discontinued.
- 01 Apr 2016 Planned End Date changed from 1 Apr 2016 to 1 Nov 2016 as reported by ClinicalTrials.gov.